Biotech China 2014
The 1st World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)
to be determinied
Prague, Prague
 The field of Viral Hepatitis is experiencing vast expansion in clinical
   trials and basic research as well as in emerging cutting-edge

   The 1st World Congress on Controversies in the Management of Viral
   Hepatitis (C-Hep) will function as a compressive forum where
   international experts share and debate state-of-the-art management
   issues, in order to outline the optimal treatment for patients.

   This innovative Congress is unique in its explicit focus on resolving
   controversies in best clinical care of patients infected with viral
   hepatitis. Resolving controversies promoted by recent advances will be
   addressed throughout the comprehensive meeting.

   Participants will have the advantage of discussing and debating these
   unresolved issues with leading world experts in all fields of Viral
   Hepatitis. Allowing ample time for speaker-audience discussion, the
   Congress aims at reaching up-to-date and agreed-upon answers to
   ongoing debates even when data remains limited, through evidence-based
   medicine and expert opinion.

   Prague, Prague, Prague, Czech Republic

   Loading (May not complete on browsers without Javascript support)...

   Try again

Event Sponsors

Schedule of Presentations:

Thursday, May 19, 2011
17:30:00 Welcome Remarks
17:40:00 Honorary Opening Lecture | Who has Hepatitis C in 2011? Rafael Esteban
17:45:00 Hepatitis B | Any controversies left? Greg Dore
Friday, May 20, 2011
08:25:00 Plenary Session 1 | Chairpersons Welcome Address
08:30:00 HCV Program Director | Hall A Rafael Esteban, Stefan Zeuzem
08:35:00 Direct Antivirals | The Future is Now
08:40:00 HCV Direct Acting Antivirals
09:00:00 Who are they? Christoph Sarrazin
09:20:00 Who needs them?
09:35:00 How to use them?
10:00:00 Coffee Break
10:30:00 Plenary Session 2 | First Line Therapy | Are there preferred options? | Hall A Stefan Zeuzem, Rafael Esteban
10:45:00 HCV Protease inhibitors | Overview of a new class of HCV drugs
10:50:00 PEG-IFNα2a vs. PEG-IFNα2b vs. New Interferons
11:00:00 PEG-IFNα2a Stefan Zeuzem
11:30:00 PEG-IFNα2b Rafael Esteban
11:45:00 New Interferons Douglas T. Dieterich
11:55:00 CME SYMPOSIUM Why DAAs will Make a Difference | A New HCV Treatment Era
12:00:00 Welcome and Introduction
12:05:00 Why DAAs will make a difference | efficacy and safety in treatment-naïve patients with HCV
12:20:00 How will previously treated patients benefit in the new HCV treatment era?
12:40:00 How will drug-drug interactions with DAAs affect patient management?
12:55:00 Does resistance matter? Understanding the mechanisms and implications
13:15:00 Summary and key learnings
13:15:00 Meeting close
13:20:00 Lunch Break
14:00:00 Plenary Session 3 | Liver Biopsies | End of the Game? | Hall A Charles Boucher
14:30:00 New diagnostics for evaluating the liver, first line Thierry Poynard
14:45:00 New diagnostics for evaluating the virus Jean Michel Pawlotsky
15:00:00 Session 6 | Frequent viral load monitoring | Necessity or Luxury? | Hall C
15:00:00 Session 4 | Is there still a need for liver biopsies?
15:00:00 Session 5 | Does drug resistance testing have a clinical role in HCV therapy? | Hall B Jonathan M. Schapiro
15:05:00 Yes Kenneth E. Sherman
15:20:00 Pro Charles Boucher
15:25:00 Necessity | Hall C Vincente Soriano
15:35:00 Con Jean Michel Pawlotsky
15:40:00 No Thierry Poynard
15:40:00 Luxury | Hall C Hans L. Tillmann
16:00:00 Coffee Break
16:30:00 Session 7 | Clinical Cases | Treatment of Hepatitis C
16:35:00 Session 7A | Case 1 | Hall A Raffaele Bruno
17:00:00 Session 7B | Case 2 | Hall B Lars Peters
17:10:00 Session 7C | Case 3 | Hall C Xavier Forns
Saturday, May 21, 2011
09:00:00 Session 8 | HIV/HCV Co-infected Patients | Time to treat or time to wait? | Hall A
09:00:00 Session 9 | Incorporating genetic markers into routine clinical care | Now or Later? | Hall B Hans L. Tillmann
09:00:00 Session 10 | Acute Hepatitis C | What is new? | Hall C Jürgen Rockstroh
09:05:00 Treat Stefan Mauss
09:05:00 Do we need ribavirin for treatment of acute hepatitis C in HIV coinfected patients? | Hall C
09:15:00 Now | Hall B Andre Rauch
09:25:00 Yes | Hall C Mark Nelson
09:30:00 Later | Hall B Ulrich Spengler
09:30:00 Wait Brian Gazzard
09:40:00 No | Hall C Martin Vogel
10:00:00 Coffee Break
10:30:00 Plenary Session 11 | HBV Therapy in 2011 | Hall A Fabien Zoulim, Maria Buti
10:45:00 Hepatitis B therapy Pietro Lampertico
11:00:00 Is Hepatitis B curable? Fabien Zoulim
11:05:00 Interferon or oral anti-HBV drugs for first line therapy?
11:10:00 Interferon Patrick Marcellin
11:30:00 Oral anti-HBV drugs Maria Buti
12:00:00 INDUSTRIAL SYMPOSIUM Unlocking New Possibilities in the Treatment of HCV G1 | The Future of Direct Acting Antivirals
13:15:00 Lunch Break
14:00:00 Plenary Session 12 | Clinical Cases | Hepatitis B | Hall A Fabien Zoulim, Thomas Berg, Maria Buti, Geoffrey Dusheiko
15:00:00 Plenary Session 13 | Hot Topics in Viral Hepatitis | Hall A Douglas T. Dieterich
15:15:00 Treatment of Hepatitis Delta Heiner Wedemeyer
15:30:00 Treatment of Hepatitis B in pregnancy Cihan Yurdaydin
15:45:00 Silibinin rescue therapy Thomas Berg
16:00:00 Coffee Break
16:30:00 Pipeline Showcase Jonathan M. Schapiro
Sunday, May 22, 2011
09:00:00 Plenary Session 14 | Management of ESLD | Hall A Heiner Wedemeyer
09:15:00 Treatment of HCC | What is new? Massimo Puoti
09:30:00 Portal hypertension | state of the art Ulrich Spengler
10:00:00 Liver Transplantation in 2011
10:30:00 Coffee Break
11:00:00 Plenary Session 15 | Beyond the Horizon | Hall A
11:05:00 Can HCV be cured without interferon?
11:35:00 Yes Heiner Wedemeyer
11:45:00 No Geoffrey Dusheiko
12:00:00 The Future is Now
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.